Express Scripts is reportedly telling U.S. drugmakers that the pricing model in place is no longer effective, and is targeting Amgen and Eli Lilly’s migraine drugs in the process.
The PBM is pushing the drugmakers to adopt a more performance-based approach by foregoing the high list price and big rebate strategy, and issuing a refund if the medications fail to deliver results in a defined timeframe.
“Let’s be more balanced,” Express Scripts Chief Medical Officer Steve Miller said. “Let’s get back to where gross-to-net is not so different.”
Eli Lilly’s CEO, David Ricks, said the drugmaker has pushed PBMs to create more performance-based agreements.
“We’ll be happy to work with them on it,” he said.